Log in

NASDAQ:AMRS - Amyris Stock Price, Forecast & News

$3.41
-0.34 (-9.07 %)
(As of 02/19/2020 06:00 AM ET)
Today's Range
$3.39
Now: $3.41
$3.93
50-Day Range
$2.56
MA: $3.09
$3.85
52-Week Range
$1.87
Now: $3.41
$5.75
Volume1.98 million shs
Average Volume1.91 million shs
Market Capitalization$359.76 million
P/E RatioN/A
Dividend YieldN/A
Beta0.84
Amyris, Inc, an integrated renewable products company, delivers alternatives to petroleum, plant, and animal-based products across a range of consumer and industry segments worldwide. It applies its bioscience solutions to convert plant sugars into hydrocarbon molecules, specialty ingredients, and consumer products. The company delivers its No Compromise products and services in markets, such as specialty and performance chemicals, flavors and fragrances, cosmetics ingredients, pharmaceuticals, and nutraceuticals. Read More…

Industry, Sector and Symbol

Industry Industrial organic chemicals
Sub-IndustryOil & Gas Refining & Marketing
SectorBasic Materials
Current SymbolNASDAQ:AMRS
CUSIP03236M10
Phone510-450-0761

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$80.42 million
Book Value($2.83) per share

Profitability

Net Income$-230,240,000.00
Net Margins-161.48%

Miscellaneous

Employees414
Market Cap$359.76 million
Next Earnings Date3/16/2020 (Estimated)
OptionableOptionable

Receive AMRS News and Ratings via Email

Sign-up to receive the latest news and ratings for AMRS and its competitors with MarketBeat's FREE daily newsletter.


Amyris (NASDAQ:AMRS) Frequently Asked Questions

What is Amyris' stock symbol?

Amyris trades on the NASDAQ under the ticker symbol "AMRS."

When did Amyris' stock split? How did Amyris' stock split work?

Amyris shares reverse split on the morning of Tuesday, June 6th 2017. The 1-15 reverse split was announced on Tuesday, June 6th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Monday, June 5th 2017. An investor that had 100 shares of Amyris stock prior to the reverse split would have 7 shares after the split.

How were Amyris' earnings last quarter?

Amyris Inc (NASDAQ:AMRS) announced its quarterly earnings data on Thursday, November, 7th. The biotechnology company reported ($0.51) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.53) by $0.02. The biotechnology company had revenue of $34.95 million for the quarter, compared to analysts' expectations of $21.60 million. View Amyris' Earnings History.

When is Amyris' next earnings date?

Amyris is scheduled to release their next quarterly earnings announcement on Monday, March 16th 2020. View Earnings Estimates for Amyris.

What guidance has Amyris issued on next quarter's earnings?

Amyris issued an update on its FY 2019 After-Hours earnings guidance on Monday, November, 25th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $$150 million, compared to the consensus revenue estimate of $$148.65 million.

What price target have analysts set for AMRS?

2 brokers have issued 12-month price objectives for Amyris' shares. Their forecasts range from $8.00 to $11.00. On average, they expect Amyris' share price to reach $9.50 in the next twelve months. This suggests a possible upside of 178.6% from the stock's current price. View Analyst Price Targets for Amyris.

What is the consensus analysts' recommendation for Amyris?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amyris in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Amyris.

Has Amyris been receiving favorable news coverage?

Media stories about AMRS stock have trended very positive this week, according to InfoTrie Sentiment. The research firm ranks the sentiment of news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Amyris earned a media sentiment score of 4.0 on InfoTrie's scale. They also gave media coverage about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the company's share price in the near term. View News Stories for Amyris.

Are investors shorting Amyris?

Amyris saw a increase in short interest in the month of January. As of January 31st, there was short interest totalling 19,160,000 shares, an increase of 11.5% from the January 15th total of 17,190,000 shares. Based on an average daily trading volume, of 1,180,000 shares, the short-interest ratio is presently 16.2 days. Currently, 38.5% of the company's stock are short sold. View Amyris' Current Options Chain.

Who are some of Amyris' key competitors?

What other stocks do shareholders of Amyris own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amyris investors own include Gevo (GEVO), Keryx Biopharmaceuticals (KERX), Inovio Pharmaceuticals (INO), Novavax (NVAX), Canopy Growth (CGC), Advanced Micro Devices (AMD), Intel (INTC), MEI Pharma (MEIP), General Electric (GE) and Amarin (AMRN).

Who are Amyris' key executives?

Amyris' management team includes the folowing people:
  • Mr. John G. Melo, Pres, CEO & Director (Age 53)
  • Ms. Kathleen Valiasek, Chief Financial Officer (Age 55)
  • Mr. Eduardo Alvarez, Chief Operating Officer (Age 55)
  • Ms. Nicole Kelsey, Gen. Counsel & Sec. (Age 52)
  • Dr. Joel R. Cherry, Pres of R&D (Age 58)

Who are Amyris' major shareholders?

Amyris' stock is owned by many different of institutional and retail investors. Top institutional investors include FMR LLC (8.01%), Pinnacle Associates Ltd. (1.29%), State Street Corp (0.83%), Essex Investment Management Co. LLC (0.42%), Goldman Sachs Group Inc. (0.29%) and Rice Hall James & Associates LLC (0.18%). Company insiders that own Amyris stock include (Mauritius) Pte Ltd Maxwell, Eduardo Alvarez, Frank Kung, John Melo, Kathleen Valiasek, L John Doerr and Patrick Y Yang. View Institutional Ownership Trends for Amyris.

Which major investors are selling Amyris stock?

AMRS stock was sold by a variety of institutional investors in the last quarter, including Barclays PLC, Goldman Sachs Group Inc., Principal Financial Group Inc., Alliancebernstein L.P., Bank of America Corp DE and Rice Hall James & Associates LLC. View Insider Buying and Selling for Amyris.

Which major investors are buying Amyris stock?

AMRS stock was purchased by a variety of institutional investors in the last quarter, including FMR LLC, Pinnacle Associates Ltd., Essex Investment Management Co. LLC, State Street Corp, Spark Investment Management LLC, Virtus ETF Advisers LLC, Levin Capital Strategies L.P. and UBS Group AG. Company insiders that have bought Amyris stock in the last two years include Eduardo Alvarez, Frank Kung, Kathleen Valiasek, L John Doerr and Patrick Y Yang. View Insider Buying and Selling for Amyris.

How do I buy shares of Amyris?

Shares of AMRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Amyris' stock price today?

One share of AMRS stock can currently be purchased for approximately $3.41.

How big of a company is Amyris?

Amyris has a market capitalization of $359.76 million and generates $80.42 million in revenue each year. The biotechnology company earns $-230,240,000.00 in net income (profit) each year or ($2.53) on an earnings per share basis. Amyris employs 414 workers across the globe.View Additional Information About Amyris.

What is Amyris' official website?

The official website for Amyris is http://amyris.com/.

How can I contact Amyris?

Amyris' mailing address is 5885 HOLLIS STREET SUITE 100, EMERYVILLE CA, 94608. The biotechnology company can be reached via phone at 510-450-0761 or via email at [email protected]


MarketBeat Community Rating for Amyris (NASDAQ AMRS)

Community Ranking:  2.0 out of 5 (star star)
Outperform Votes:  303 (Vote Outperform)
Underperform Votes:  470 (Vote Underperform)
Total Votes:  773
MarketBeat's community ratings are surveys of what our community members think about Amyris and other stocks. Vote "Outperform" if you believe AMRS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AMRS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/19/2020 by MarketBeat.com Staff

Featured Article: Dividend Achievers

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel